Stock Track | Insmed Soars 12% Pre-market Despite Q3 Loss, Buoyed by Optimistic Full-Year Outlook

Stock Track

Oct 30, 2025

Shares of Insmed (INSM) surged 12.01% in pre-market trading on Thursday, despite reporting disappointing third-quarter 2025 financial results. The biopharmaceutical company's stock rally appears to be driven by an optimistic full-year revenue outlook, overshadowing the quarterly performance.

Insmed reported a third-quarter net loss of $370 million, with earnings per share (EPS) of -$1.75. The company's revenue for the quarter came in at $28.1 million, significantly below the IBES estimate of $114.4 million. Despite these underwhelming figures, investors seem to be focusing on the company's forward-looking statements.

The key driver behind the stock's pre-market surge appears to be Insmed's full-year revenue outlook. The company projects fiscal year 2025 revenue to be in the range of $420-430 million. This positive guidance suggests that Insmed expects a substantial improvement in its performance in the coming quarters, which has evidently sparked investor optimism. The market's reaction indicates that traders are looking beyond the current quarter's results and betting on the company's future potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1173884071"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1173884071\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1173884071?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1173884071","market":"us","top_or_hot":-1,"title":"Stock Track | Insmed Soars 12% Pre-market Despite Q3 Loss, Buoyed by Optimistic Full-Year Outlook","media":"Stock Track","content":"<p>Shares of Insmed (INSM) surged 12.01% in pre-market trading on Thursday, despite reporting disappointing third-quarter 2025 financial results. The biopharmaceutical company's stock rally appears to be driven by an optimistic full-year revenue outlook, overshadowing the quarterly performance.</p>\n\n<p>Insmed reported a third-quarter net loss of $370 million, with earnings per share (EPS) of -$1.75. The company's revenue for the quarter came in at $28.1 million, significantly below the IBES estimate of $114.4 million. Despite these underwhelming figures, investors seem to be focusing on the company's forward-looking statements.</p>\n\n<p>The key driver behind the stock's pre-market surge appears to be Insmed's full-year revenue outlook. The company projects fiscal year 2025 revenue to be in the range of $420-430 million. This positive guidance suggests that Insmed expects a substantial improvement in its performance in the coming quarters, which has evidently sparked investor optimism. The market's reaction indicates that traders are looking beyond the current quarter's results and betting on the company's future potential.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Insmed Soars 12% Pre-market Despite Q3 Loss, Buoyed by Optimistic Full-Year Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Insmed Soars 12% Pre-market Despite Q3 Loss, Buoyed by Optimistic Full-Year Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-30 19:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Insmed (INSM) surged 12.01% in pre-market trading on Thursday, despite reporting disappointing third-quarter 2025 financial results. The biopharmaceutical company's stock rally appears to be driven by an optimistic full-year revenue outlook, overshadowing the quarterly performance.</p>\n\n<p>Insmed reported a third-quarter net loss of $370 million, with earnings per share (EPS) of -$1.75. The company's revenue for the quarter came in at $28.1 million, significantly below the IBES estimate of $114.4 million. Despite these underwhelming figures, investors seem to be focusing on the company's forward-looking statements.</p>\n\n<p>The key driver behind the stock's pre-market surge appears to be Insmed's full-year revenue outlook. The company projects fiscal year 2025 revenue to be in the range of $420-430 million. This positive guidance suggests that Insmed expects a substantial improvement in its performance in the coming quarters, which has evidently sparked investor optimism. The market's reaction indicates that traders are looking beyond the current quarter's results and betting on the company's future potential.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"","article_id":"1173884071","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1173884071","pubTimestamp":1761822738,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Insmed (INSM) surged 12.01% in pre-market trading on Thursday, despite reporting disappointing third-quarter 2025 financial results. The biopharmaceutical company's stock rally appears to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed"},"translate_title":"个股追踪|Insmed尽管第三季度亏损，但受乐观的全年前景提振，盘前仍飙升12%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1},"content_text":"Shares of Insmed (INSM) surged 12.01% in pre-market trading on Thursday, despite reporting disappointing third-quarter 2025 financial results. The biopharmaceutical company's stock rally appears to be driven by an optimistic full-year revenue outlook, overshadowing the quarterly performance.\nInsmed reported a third-quarter net loss of $370 million, with earnings per share (EPS) of -$1.75. The company's revenue for the quarter came in at $28.1 million, significantly below the IBES estimate of $114.4 million. Despite these underwhelming figures, investors seem to be focusing on the company's forward-looking statements.\nThe key driver behind the stock's pre-market surge appears to be Insmed's full-year revenue outlook. The company projects fiscal year 2025 revenue to be in the range of $420-430 million. This positive guidance suggests that Insmed expects a substantial improvement in its performance in the coming quarters, which has evidently sparked investor optimism. The market's reaction indicates that traders are looking beyond the current quarter's results and betting on the company's future potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}